Select Page

The Infinium Global Research analyzes the Hydroxychloroquine Market over the period of 2020 to 2026. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global hydroxychloroquine market. It will help a lot of decision makers to develop strategies and find new opportunities in the global markets of hydroxychloroquine. The report covers market changing aspects including drivers, restraints, opportunities, and trends expected to encouragement the expansion of the hydroxychloroquine market during the period.

Hydroxychloroquine (HCQ), one of the anti-malarial drugs has received an unprecedented amount of interest as a potential treatment for COVID-19. The drug has shown strong antiviral effects on the coronavirus infection and had a significant effect, both in terms of clinical outcome and viral clearance. 

Currently, 211 countries are infected by COVID-19 and 3.04 Million people are infected with the virus. As coronavirus COVID-19 pandemic is growing as a global health crisis, countries are aggressively taking precautionary measures to contain the spread of the virus. This in turn will augment the demand for HCQ over the coming days to contain the spread of virus. Furthermore, increasing government funding in controlling the spread of the pandemic is fuelling the growth of the market. 

We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026. 

The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report: 

Oral Forms of Hydroxychloroquine Drug to Hold the Largest Share in the Market

Hydroxychloroquine  belongs to a class of medications known as disease-modifying antirheumatic drugs (DMARDs) and is most commonly used in treatment of malaria.   This medication is also used to treat certain auto-immune diseases such as lupus and rheumatoid arthritis. Moreover, the drug  is one of the first potential agents to demonstrate the ability to slow the SARS-CoV-2, the novel coronavirus, in a laboratory, which has prompted an increase in demand for the oral Hydroxychloroquine in the global markets for the treatment of COVID-19. 

Furthermore, ease in administration has also increased the demand for the oral forms of Hydroxychloroquine drug. The report on the “Global Hydroxychloroquine market” offers an in-depth analysis of the segments such as Route of Administration (Oral and Intravenous), Strength (100mg, 250mg & 500mg), and Application (Rheumatoid Arthritis, Malaria, COVID-19, Others).

Asia Pacific to Emerge as the Largest Consumer of Hydroxychloroquine Over the Forecast Years

Among the regions, North America will dominate the global market over the forecast years owing to the rising use of the drug for COVID-19 treatment in 2020. The U.S. is the world’s most affected country by coronavirus currently, by number of cases, which has increased the demand for the drugs in the North America region. 

The U.S. has 1.01 Million confirmed cases of COVID-19. Europe will hold the second largest share as seven European countries are among the ten most affected countries with coronavirus. Furthermore, as more European countries are witnessing a surge in cases, the usage of Hydroxychloroquine is expected to intensify in Europe over 2020. Moreover, in the long term, the developing regions will emerge as the predominant users of Hydroxychloroquine due to the increasing cases of malaria in such countries.

Get this Section as a Free Customization in the Report along with Discount on the Study: 

Hydroxychloroquine Market to Witness a Massive Surge in Production Due to the Covid-19 Pandemic

The Hydroxychloroquine market is highly consolidated. Indian companies such as IPCA and Zydus Cadila are the major manufacturers of Hydroxychloroquine, manufacturing upto 60% of the world's supply of hydroxychloroquine. The other manufacturers of the drug include Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Rising Pharma Holdings Inc, Abcam plc, Mylan N.V, and Abbott Laboratoris. 

Therefore, major economies such as the U.S. and EU are relying on Indian vendors for drug supplies causing them to ramp up its production activities. The Indian pharmaceutical companies have also ramped up the monthly production of anti-malarial drug Hydroxychloroquine (HCQ) four times to 40 metric tonnes (MT) by the end of this month and five to six times to over 70 metric tonnes (MT) by next month. The plan to step up production came after the Government of India indicated it will help countries in dire need of the drug to fight novel coronavirus. 

Furthermore, owing to the broken supply chain management and lesser possibility of receiving drugs and APIs from China, this can be an opportunity for Indian manufacturers to establish themselves and expand further in the global market. Infinium Global Research’s recent report on the global Hydroxychloroquine is an encompassment of such recent developments in the global marketplace. The report delivers insights into the recent developments by leading players that have contributed to the growth of the market and also estimates the impact of recent developments the global market. 

Browse Detailed Report@

About Us

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide the knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.